Case 1: 72-Year-Old Woman With Small Cell Lung Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Case 1: 72-Year-Old Woman With Small Cell Lung Cancer | Targete…
Aug 31, 2020
targetedonc.com
Clinical Data from CheckMate 648 and KEYNOTE 590 | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Clinical Data from CheckMate 648 and KEYNOTE 590 | Targeted Onc…
3 weeks ago
targetedonc.com
Case Overview: A 58-Year-Old Woman With Polycythemia Vera | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Case Overview: A 58-Year-Old Woman With Polycythemia Vera | …
Apr 30, 2019
targetedonc.com
Targeted Vaccine Leads to Broad Immune Response in Pancreatic Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Targeted Vaccine Leads to Broad Immune Response in Pancreatic C…
4 months ago
targetedonc.com
Leveraging ctDNA Status to Guide Treatment Strategies in Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Leveraging ctDNA Status to Guide Treatment Strategies in Breast Ca…
2 weeks ago
targetedonc.com
MRD Testing: Guidelines and Clinical Decision-Making in Treatment-Naive CLL | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
MRD Testing: Guidelines and Clinical Decision-Making in Treat…
5 months ago
targetedonc.com
Adjuvant Cemiplimab: New Standard for High-Risk CSCC Recurrence | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Adjuvant Cemiplimab: New Standard for High-Risk CSCC Rec…
3 months ago
targetedonc.com
The Targeted Pulse: Immunotherapy’s Success in Tripl…
9 months ago
targetedonc.com
Ongoing Study of Adjuvant Elacestrant: Phase 3 ELEGANT | T…
5 months ago
targetedonc.com
Current Evidence and Future Directions | Targeted Oncology - I…
4 months ago
targetedonc.com
TRANSFORM Trial: Clinical Perspectives in Liso-Cel CAR T-C…
4 months ago
targetedonc.com
Key Updates From the CELESTIAL Trial Presented at ASH 2024 | Targ…
11 months ago
targetedonc.com
ASCO 2025: Clinical Efficacy From the COMMANDS Trial for Luspater…
5 months ago
targetedonc.com
Optimizing Phlebotomy Strategies: Frequency and Clinical Considerat…
7 months ago
targetedonc.com
Beyond SC Daratumumab: Emerging Therapeutic Approache…
1 week ago
targetedonc.com
Evaluating Belzutifan for Clear Cell Renal Cell Carcinoma Treatment | …
6 days ago
targetedonc.com
COMFORT Trials: Applying Evidence to Intermediate-Risk My…
7 months ago
targetedonc.com
Second-Line Therapy in Advanced HCC: Treatment Considerations a…
8 months ago
targetedonc.com
Unmet Needs Persist for Patients with Melanoma | Targeted Oncolo…
Jul 13, 2024
targetedonc.com
Evolving Treatment Landscape in Metastatic Castration-Resistant Pr…
6 months ago
targetedonc.com
Safety Challenges of Oncolytic Virus Therapy | Targeted Oncology - Im…
Jun 12, 2024
targetedonc.com
MonumenTAL-1: Data Updates of Talquetamab, a GPRC5D-Directed …
Dec 13, 2024
targetedonc.com
Advantages of SC HER2 Therapy Over IV Administration in Breast C…
Mar 7, 2024
targetedonc.com
FDA Approvals of Systemic Therapy for Steroid-Refractory cGVHD | Ta…
5 days ago
targetedonc.com
PD-L1 Testing and Its Role in Lung Cancer Treatment Decision-Makin…
5 days ago
targetedonc.com
Risk Stratification of Patients with Advanced Renal Cell Carcinoma | …
6 days ago
targetedonc.com
The Differences Between mCRPC and nmCRPC | Targeted Oncolog…
Jul 17, 2019
targetedonc.com
Understanding the Mechanism and Sensitivity of BCL-2 Inhibitors | Ta…
11 months ago
targetedonc.com
Overview of the Systemic Treatment Options for Metastatic or Relapse…
Sep 21, 2023
targetedonc.com
Phase 3 ARANOTE Study of ADT Darolutamide | Targeted Oncolog…
11 months ago
targetedonc.com
See more videos
Static thumbnail place holder